HomeCompareYMTX vs STAG

YMTX vs STAG: Dividend Comparison 2026

YMTX yields 105.82% · STAG yields 3.99%● Live data

vsPost on X →
After 10 years · $10,000 invested · DRIP enabled
🏆 YMTX wins by $4.91M in total portfolio value
10 years
YMTX
YMTX
● Live price
105.82%
Share price
$1.89
Annual div
$2.00
5Y div CAGR
0%
Payout ratio
50%
After 10 yrs · $10,000 · DRIP
Portfolio value
$4.93M
Annual income
$1,723,843.10
Full YMTX calculator →
STAG
STAG Industrial Inc.
● Live price
3.99%
Share price
$36.80
Annual div
$1.47
5Y div CAGR
1%
Payout ratio
72%
After 10 yrs · $10,000 · DRIP
Portfolio value
$19.4K
Annual income
$606.20
Full STAG calculator →

Portfolio growth — YMTX vs STAG

📍 YMTX pulled ahead of the other in Year 1

Annual dividend income

🛡️

Recession Test — Did They Cut Dividends?

How each stock treated shareholders during the 3 biggest crises of the last 20 years

Crisis PeriodYMTXSTAG
2008–2009
GFC
— No data— No data
2020 Q1–Q2
COVID
— No data— No data
2022 Q4
Rate Hike
— No data— No data
Based on dividend payment history. "Increased" = dividend grew during crisis. "Maintained" = held within 3%. "Cut" = reduced by more than 3%.
📅

Dividend Calendar Overlap

Combined, YMTX + STAG cover 0 of 12 monthsgood coverage

Jan
Feb
Mar
Apr
May
Jun
Jul
Aug
Sep
Oct
Nov
Dec
YMTX pays
STAG pays
Both pay
Neither
💰

Tax Bracket Optimizer

Which stock is actually better after tax? Adjust your rate to find out.

YMTX
Annual income on $10K today (after 15% tax)
$8,994.71/yr
After 10yr DRIP, annual income (after tax)
$1,465,266.64/yr
STAG
Annual income on $10K today (after 15% tax)
$339.54/yr
After 10yr DRIP, annual income (after tax)
$515.27/yr
At 15% tax rate, YMTX beats the other by $1,464,751.37/year in after-tax income after 10 years on $10,000
⚖️

Lazy Portfolio Split Optimizer

What's the optimal mix of YMTX + STAG for your $10,000?

YMTX: 50%STAG: 50%
100% STAG50/50100% YMTX
Portfolio after 10yr
$2.47M
Annual income
$862,224.65/yr
Blended yield
34.85%
📊

Analyst Conviction Gap

Where Wall Street is most bullish on STAG right now

YMTX
Analyst Ratings
2
Buy
Consensus: Buy
Altman Z
-21.9
Piotroski
3/9
STAG
Analyst Ratings
9
Buy
9
Hold
3
Sell
Consensus: Buy
Price Target
$45.00
+22.3% upside vs current
Range: $39.00 — $59.00
Altman Z
1.2
Piotroski
5/9
Analyst ratings via FMP. Altman Z-Score: >3.0 safe, 1.81–3.0 grey zone, <1.81 distress. Piotroski: 7–9 strong, 0–3 weak.
🏛️

Copy Congress — What Are Politicians Buying?

Senate & House STOCK Act disclosures (last 90 days)

YMTX buys
0
STAG buys
0
No recent congressional trades found for YMTX or STAG in the last 90 days.
STOCK Act mandates disclosure within 45 days of transaction. Data via FMP.Full tracker →
MetricYMTXSTAG
Forward yield105.82%3.99%
Annual dividend / share$2.00$1.47
Payout ratio50%72%
1-year div growth0%0.5%
5-year div CAGR0%1%
Portfolio after 10y$4.93M$19.4K
Annual income after 10y$1,723,843.10$606.20
Total dividends collected$4.43M$5.0K
Payment frequencyquarterlymonthly
SectorStockREIT
Analyst consensusBuyBuy

Year-by-year: YMTX vs STAG ($10,000, DRIP)

YearYMTX PortfolioYMTX Income/yrSTAG PortfolioSTAG Income/yrGap
1← crossover$21,282$10,582.01$10,723$403.45+$10.6KYMTX
2$43,819$21,047.33$11,490$423.42+$32.3KYMTX
3$87,387$40,500.83$12,302$444.01+$75.1KYMTX
4$168,990$75,485.74$13,161$465.24+$155.8KYMTX
5$317,245$136,425.12$14,069$487.12+$303.2KYMTX
6$578,807$239,355.52$15,029$509.63+$563.8KYMTX
7$1,027,455$408,130.85$16,042$532.80+$1.01MYMTX
8$1,776,463$677,086.81$17,112$556.61+$1.76MYMTX
9$2,994,908$1,094,092.83$18,241$581.08+$2.98MYMTX
10$4,928,395$1,723,843.10$19,431$606.20+$4.91MYMTX

YMTX vs STAG: Complete Analysis 2026

YMTXStock

Yumanity Therapeutics Inc., a clinical stage biopharmaceutical company, engages in the research and development of treatments for neurodegenerative diseases caused by protein misfolding. The company focuses on discovering disease-modifying therapies to treat neurodegenerative diseases, including Parkinson's disease, dementia with Lewy bodies, multiple system atrophy, amyotrophic lateral sclerosis, and frontotemporal lobar degeneration. Its lead program is YTX-7739, a novel small molecule that is in Phase I clinical trial for the treatment of Parkinson's disease and related disorders of a-synuclein. The company is also developing YTX-9184, which is in preclinical studies to treat neurological disorders. Yumanity Therapeutics Inc. has a license and research collaboration agreement with Merck Sharp & Dohme Corp. The company was founded in 2014 and is headquartered in Boston, Massachusetts.

Full YMTX Calculator →

STAGREIT

STAG Industrial is a single-tenant industrial REIT paying monthly dividends. Its portfolio of 500+ warehouses and distribution centers benefits from e-commerce growth. Amazon is its largest tenant. Monthly income frequency makes it attractive for investors who prefer regular cash flow over quarterly payments.

Full STAG Calculator →
📬

Get this YMTX vs STAG comparison by email

Save your analysis + weekly dividend insights. Free forever.

More comparisons

YMTX vs SCHDYMTX vs JEPIYMTX vs OYMTX vs KOYMTX vs MAINYMTX vs PLDYMTX vs EQRYMTX vs VICI

⚠️ Educational purposes only. Not financial advice. Congressional trades sourced from SEC STOCK Act filings via FMP. Past performance does not guarantee future results.